YOLFTbeta
Nuformix plc

Nuformix plc

NFX · LSE · Healthcare / Biotechnology

0.0908GBX-0.00 (-4.42%)

Price History

Full chart

Market Stats

Previous Close0.095
Open0.095
Day Range0.0836 – 0.10
52-Week Range0.12 – 0.555
Volume32.70M
Market Cap3.52M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta1.55
50-Day Avg0.1521
200-Day Avg0.1935

About

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Daniel John Gooding
  • Employees3
  • Headquarters60 Gracechurch Street, London, United Kingdom, EC3V 0HR, UK
  • Websitehttps://www.nuformix.com

Leadership

  • Dr. Daniel John GoodingExecutive Director · b. 1973
  • Dr. Joanne M. HollandConsultant · b. 1975
  • Shaun ZulafqarCompany Secretary

Financials

Income Statement

Currency: GBP2014-07-312015-07-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312023-09-302024-09-302025-09-30
Total Revenue183.86K174.00K607.50K015.00K610.00K535.00K195.55K50.00K0-00
Growth (%)--5.36%+249.14%-100.00%-+3966.67%-12.30%-63.45%-74.43%-100.00%---
Cost of Revenue39.08K66.06K71.85K86.19K203.87K537.53K333.60K108.83K38.67K036.75K29.17K28.63K
Gross Profit144.78K107.94K535.65K-86.19K-188.87K72.47K201.41K86.72K11.33K0-36.75K-29.17K-28.63K
Gross Margin78.74%62.03%88.17%--1259.12%11.88%37.65%44.35%22.66%----
Operating Expense-139.19K330.27K886.07K598.87K1.77M1.88M1.12M1.46M1.28M761.30K581.90K3.62M631.94K
Operating Income283.97K-222.33K-350.42K-685.06K-1.96M-1.81M-918.18K-1.37M-1.27M-761.30K-618.65K-3.65M-660.57K
Operating Margin154.45%-127.78%-57.68%--13076.71%-296.81%-171.62%-702.62%-2540.54%----
EBITDA299.28K-185.64K288.10K-685.06K-851.93K-1.76M-832.90K-1.28M-1.23M-724.40K-581.90K-477.19K-631.94K
EBITDA Margin162.78%-106.69%47.42%--5679.54%-288.77%-155.68%-654.37%-2466.59%----
Net Income279.54K-204.16K-350.42K-685.06K-1.84M-1.66M-756.38K-1.25M-1.11M-760.14K-572.98K-3.64M-652.59K
Net Income Margin152.04%-117.33%-57.68%--12255.09%-272.33%-141.38%-641.01%-2217.99%----
R&D---472.00K876.58K1.45M524.98K362.88K572.92K-163.40K70.91K95.33K
R&D as % of Total Revenue----5843.87%237.58%98.13%185.57%1145.84%----
Interest Expense---1.76K11.06K28.41K15.30K3.05K00---
Interest Expense % of Total Revenue----73.74%4.66%2.86%1.56%0.00%----

Balance Sheet

Currency: GBP2014-07-312015-07-312015-12-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312023-09-302024-09-302025-09-30
Total Assets534.27K281.00K724.59K544.79K19.62K5.03M4.63M5.13M6.01M4.98M4.50M4.42M970.54K1.02M
Total Liabilities287.26K391.86K69.76K42.45K199.21K534.00K819.52K383.91K324.62K237.86K273.56K222.99K254.97K263.92K
Total Equity93.31K-110.86K-502.34K-179.59K4.49M3.82M4.74M5.69M4.74M4.23M4.20M715.57K754.93K
Cash102.81K62.26K684.90K502.21K5.89K338.17K4.26K543.77K1.67M464.10K259.26K202.55K20.21K97.55K
Total Debt----187.91K22.96K15.11K75.39K------
Net Debt-102.81K-62.26K-684.90K-502.21K182.02K-315.21K10.85K-468.38K-1.67M-464.10K-259.26K-202.55K-20.21K-97.55K

Cash Flow

Currency: GBP2014-07-312015-07-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312023-09-302024-09-302025-09-30
Operating Cash Flow155.8586.8-350.55K-496.32K-1.53M-299.34K-727.60K-848.22K-1.35M-433.10K-546.23K-331.88K-614.61K
Investing Cash Flow-33.71-124.39-68.67-93.25K-100.62K-27.28K-43.20K43.72K--33.33K--
Financing Cash Flow-38.11-2.96852.76K-19.60K1.97M-7.29K1.31M1.93M139.98K228.26K189.79K149.54K691.95K
Capital Expenditure2.321.532.2993.25K44.09K1.28K43.20K60500200
Free Cash Flow153.5485.27-350.55K-589.57K-1.58M-300.62K-770.80K-848.83K-1.35M-433.10K-397.49K-331.88K-614.61K
FCF to OCF98.52%98.24%100.00%118.79%102.88%100.43%105.94%100.07%100.00%100.00%72.77%100.00%100.00%

Key Statistics & Ratios

Market Cap3.52M
Enterprise Value2.59M
Trailing P/E0.00
Forward P/E0.00
Price / Sales43.69
Price / Book2.15
EPS0.00
Book Value0.001
Revenue (TTM)0
Gross Profit (TTM)48.30K
EBITDA-602.12K
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-50.94%
Return on Assets-27.17%
Shares Outstanding2.61B
Shares Float2.50B
Beta1.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%